Search - tctmd.com

Displaying 861 - 880 of 2580

Sort: Relevancy | Date

Presentation TCT 2015

The Case for TAVR Expansion to Lower-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Nicolo Piazza

October 11, 2015

Presentation TCT 2015

Which Aortic Stenosis Patients Are Definitely NOT TAVR Candidates in 2015?

Presenter: Martin B. Leon, Neil E. Moat, Thomas Walther

October 11, 2015

Presentation TCT 2015

What Are the Indications for TAVR in 2015? According to Real-World Clinical Practice

Presenter: Martin B. Leon, Neil E. Moat, Axel Linke

October 11, 2015

Presentation TCT 2015

What Are the Indications for TAVR in 2015? According to the EU and US Guidelines

Presenter: Martin B. Leon, Neil E. Moat, Alec S. Vahanian

October 11, 2015

Presentation TCT 2015

KEYNOTE LECTURE: Redefining Aortic Stenosis Use of Advanced Imaging, Hemodynamics, Computational Models, and Clinical Data to Revise Trigger Points for Treatment

Presenter: Eberhard Grube, Michael J. Mack, Elazer R. Edelman

October 11, 2015

Presentation TCT 2015

Which Patients for TAVR? Will Surgical Risk Stratification Remain the Dominant Strategy in the Future?

Presenter: Eberhard Grube, Michael J. Mack, John G. Webb

October 11, 2015

Presentation TCT 2015

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure Inevitable Decline!

Presenter: Eberhard Grube, Michael J. Mack, Ganesh Manoharan

October 11, 2015

Presentation TCT 2015

Obtaining Informed Consent in Difficult Scenarios Case 2: The Elderly Patient Referred for TAVR

Presenter: David A. Cox, Thomas D. Stuckey, Marian C. Hawkey

October 11, 2015

Presentation TCT 2015

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure That Would Be a Mistake!

Presenter: Eberhard Grube, Michael J. Mack, A. Pieter Kappetein

October 11, 2015

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Noninvasive Cardiologists Perspective

Presenter: Eberhard Grube, Michael J. Mack, Robert O. Bonow

October 11, 2015

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Presenter: Eberhard Grube, Michael J. Mack

October 11, 2015

Presentation TCT 2015

TAVR is a Breakthrough Technology: Important Milestones and Emerging Controversies

Presenter: Eberhard Grube, Michael J. Mack, Raj Makkar

October 11, 2015

Presentation TCT 2015

Introduction

Presenter: Eberhard Grube, Michael J. Mack, Martin B. Leon

October 11, 2015

Presentation TCT 2015

TAVR and MitraClip: How Can We Afford These Products?

Presenter: Robert J. Applegate, Ehtisham Mahmud, James B. Hermiller Jr

October 11, 2015

Presentation TCT 2015

Five by Five: TAVR Lean Initiatives

Presenter: Marian C. Hawkey, Katie Della Mora

October 11, 2015

Presentation TCT 2015

TAVR Clinical Pathways: Individualized Plans of Care

Presenter: Marian C. Hawkey, Sandra Lauck

October 11, 2015

Presentation TCT 2015

Case Presentations/Taped TAVR Case Segments

Presenter: Samir R. Kapadia, Samir R. Kapadia, Ganesh Manoharan, Ian T. Meredith

October 11, 2015

Presentation TCT 2015

Predictors and Clinical Outcomes of Permanent Pacemaker Implantation After TAVR

Presenter: Marian C. Hawkey, Ganesh Manoharan

October 11, 2015

Presentation TCT 2015

Neuroprotection During TAVR

Presenter: Marian C. Hawkey, Samir R. Kapadia

October 11, 2015

News Conference News TCT 2015

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

October 11, 2015

Advertisement

The Case for TAVR Expansion to Lower-Risk Patients

Which Aortic Stenosis Patients Are Definitely NOT TAVR Candidates in 2015?

What Are the Indications for TAVR in 2015? According to Real-World Clinical Practice

What Are the Indications for TAVR in 2015? According to the EU and US Guidelines

KEYNOTE LECTURE: Redefining Aortic Stenosis Use of Advanced Imaging, Hemodynamics, Computational Models, and Clinical Data to Revise Trigger Points for Treatment

Which Patients for TAVR? Will Surgical Risk Stratification Remain the Dominant Strategy in the Future?

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure Inevitable Decline!

Obtaining Informed Consent in Difficult Scenarios Case 2: The Elderly Patient Referred for TAVR

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure That Would Be a Mistake!

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Noninvasive Cardiologists Perspective

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

TAVR is a Breakthrough Technology: Important Milestones and Emerging Controversies

Introduction

TAVR and MitraClip: How Can We Afford These Products?

Five by Five: TAVR Lean Initiatives

TAVR Clinical Pathways: Individualized Plans of Care

Case Presentations/Taped TAVR Case Segments

Predictors and Clinical Outcomes of Permanent Pacemaker Implantation After TAVR

Neuroprotection During TAVR

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content